

Voretigene neparvovec-rzyl (Luxturna) ______Prior Authorization Form/Prescription

Telephone: (800) 514-0083 option 2 Fax: (866) 374-1579

Date: _____ Date Medication Required: ____ Ship to: O Physician O Patient's Home O Other: _

Last Name:	First Na	ame.		Middle:	DOB:	/	/		
Address:	THSCINC	inc.	City:	Wildule.		/ State:		 /ip:	
Daytime Phone:		Evening Phone	,	5	Sex:	Male	_	male	
Insurance Information (Attach copi	es of cards)	Lvening i none	•					marc	
Primary Insurance:			Secondary Insurance	ce:					
ID #	Group #		ID #			Group #			
City:	State:		City:			State:			
Physician Information									
Name:		Sp	ecialty:			NPI:			
Address:			City:			State:	Zij	o:	
Phone #:	Secure	Fax #:		Office Co	ntact:				
Primary Diagnosis									
ICD-10 Code:									
Retinal dystrophy (Leber congenital ar	naurosis)	_Other:							
Prescription Information MEDICATION STRENGTH			DIDECTIONS					DEFULC	
Luxturna (voretigene			DIRECTIONS			QUAN	IIIY	REFILLS	
neparvovec-rzyl)									
Clinical Information *	**** Please s	ubmit supporti	ng clinical docum	entation *****	:				
INITIAL THERAPY CONTINUATION OF THERAPY; Therapy start date:									
 Has patient had a positive response to the prescribed therapy? Yes No Not applicable Has patient previously been treated with Luxturna in the requested treatment eye(s)? Yes No How many days have passed since treatment of first eye? days Complete this section ONLY if the patient is <u>initiating therapy OR if the patient is new to this health plan:</u> Is therapy prescribed by or in consultation with an ophthalmologis? Yes No Is diagnosis confirmed by presence of biallelic <i>RPE65</i> gene mutations? Yes No Does patient have sufficient viable retinal cells evidenced by any of the following? Yes **Mark all that apply** No Retinal thickness on spectral domain optical coherence tomography (i.e., areas of retina with thickness measurements > 100 microns within the posterior pole) Fundus photography (i.e., presence of neural retina) Does patient have significant vision loss evidenced by any of the following? Yes **Mark all that apply** No Visual acuity of 20/60 or worse in both eyes Visual field less than 20 degrees in any meridian Has patient received intraocular surgery within the prior 6 months? Yes No Please document patient's baseline Multi-Luminance Mobility Testing (MLMT) score: log10(cd/m²) Complete this section ONLY for indications <u>other</u> than retinal dystrophy: 11. Has patient tried and failed, or is contraindicated to, accepted standards of care? Yes No **If yes, submit documentation and answer the following:**									
 a. Please list all previous therapies: b. Was patient adherent to previously tried therapies? Yes No No, patient intolerant to drug 									
Physician's Signature:			D	ate:				DAW	



Voretigene neparvovec-rzyl (Luxturna)

Prior Authorization Form/Prescription

Telephone: (800) 514-0083 option 2 Fax: (866) 374-1579

 Date:

 Date Medication Required:

 Ship to: O Physician
 O Patient's Home
 O Other:

INFORMATION BELOW IS TO BE COMPLETE BY THE HEALTH PLAN/EPS PA STAFF							
Authorization Information							
Authorization number:		Decision Due Date:					
		Coverage:					
J-Code:		□ State excludes	COB (secondary)				
Line of Business:							
Commercial	Health Insurance Marketplace	Benefit:					
Medicaid	Medicare	Medical	Pharmacy				
Criteria:							
Centene Policy							
Date Policy last reviewed/approved by plan (we want to be sure we are using the version approved by your plan):							
□ State Specific (please include policy)							
Medicare only criteria for CY2019 and CY2020:							
□ PART B use LCD or NCD □ PART D use MCPD.PA.247 Tier and Formulary Exceptions Request Criteria							